Preferred Label : Tilogotamab;
NCIt synonyms : HexaBody-DR5-01/DR5-05; Hx-DR5-01/05; HexaBody-DR5/DR5; DR5 HexaBody Agonist GEN1029;
NCIt definition : An agonistic hexamer formation-enhanced mixture of two antibodies (HexaBody) that
target two separate epitopes on death receptor type 5 (DR5; TNFRSF10B; tumor necrosis
factor-related apoptosis-inducing ligand receptor 2; TRAILR2), with potential antineoplastic
activity. Upon administration, tilogotamab specifically binds to and activates DR5.
This results in the activation of caspase cascades and the induction of apoptosis
in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor
necrosis factor receptor superfamily (TNFRSF), is involved in the promotion of caspase-dependent
apoptosis. Compared to other DR5 antibody-based agonists, the antibodies in GEN1029
(DR5-01 and DR5-05) elicit increased receptor activation because they exhibit enhanced
formation of antibody hexamers and receptor clusters at the cell surface due to E430G
mutations in the Fc domains of both antibodies.;
UNII : 1BU5EGF80S;
CAS number : 2109731-10-2;
Molecule name : GEN1029; GEN 1029;
NCI Metathesaurus CUI : CL554487;
Origin ID : C153259;
UMLS CUI : C5418248;
Semantic type(s)
- concept_is_in_subset
- has_target
